Sign In
Buy CRSP
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus
02:03pm, Thursday, 14'th Apr 2022 Zacks Investment Research
We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates fo
Is Now the Time to Bet on This Game-Changing Stock?
12:00pm, Thursday, 14'th Apr 2022 The Motley Fool
This company's targeting a market with explosive growth.
CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030
02:45pm, Wednesday, 13'th Apr 2022 The Motley Fool
The only thing standing in the way is the clinical trials process, which takes time and patience.
Another Nasdaq Bear Market on the Way? 3 Great Stocks to Buy Anyway
09:52am, Wednesday, 13'th Apr 2022 The Motley Fool
Bear, shmear. These stocks are great picks to buy no matter what the Nasdaq does next.
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
08:01pm, Tuesday, 12'th Apr 2022 GlobeNewswire Inc.
ZUG, Switzerland and CAMBRIDGE, Mass., April 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for
3 Best Life Sciences Stocks to Buy Now
12:25pm, Friday, 08'th Apr 2022
Thinking about digging into immunization stocks? Let's look more broadly, into life sciences stocks.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
08:01pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
ZUG, Switzerland and CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
04:01pm, Thursday, 07'th Apr 2022
ZUG, Switzerland and CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for se
Vertex (VRTX) Stock Rallies 27% in a Year: What Lies Ahead?
11:47am, Wednesday, 06'th Apr 2022 Zacks Investment Research
In 2022, Vertex (VRTX) expects continued revenue growth as there are more than 25,000 patients who are addressable with Vertex's CF therapies.
Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies
04:17pm, Friday, 01'st Apr 2022 Zacks Investment Research
Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.
Worried About Rising Interest Rates? These 2 Growth Stocks Could Help
02:45pm, Friday, 01'st Apr 2022 The Motley Fool
Rate hikes shouldn't rattle these stocks as their businesses carry relatively modest debt.
9 Wave Setups To Watch (Video)
12:41pm, Friday, 01'st Apr 2022
Some of these stocks present long opportunities as they pull back.
ARKK: Cathie Wood's Secret Selling
03:10pm, Thursday, 31'st Mar 2022 Seeking Alpha
ARKK ETF has found a way to generate some fresh capital for purchases. Seven names have been sold but don't appear in the daily e-mail. See more on ARKK here.
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
12:15pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
How to future-proof your stock investments and outperform the market at the same time
05:49pm, Saturday, 26'th Mar 2022 MarketWatch
Garvin Jabusch at the Shelton Green Alpha Fund girds against global systemic risk.
